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Ever since the first genome-wide association studies (GWAS) on coronary artery disease
(CAD), the Chr9p21 risk locus has emerged as a top signal in GWAS of atherosclerotic
cardiovascular disease, including stroke and peripheral artery disease. The CAD risk
SNPs on Chr9p21 lie within a stretch of 58 kilobases of non-protein-coding DNA,
containing the gene body of the long noncoding RNA (lncRNA) antisense non coding
RNA in the INK4 locus (ANRIL). How risk is affected by the Chr9p21 locus in molecular
detail is a matter of ongoing research. Here we will review recent advances in the
understanding that ANRIL serves as a key risk effector molecule of atherogenesis at
the locus. One focus of this review is the shift in understanding that genetic variation
at Chr9p21 not only affects the abundance of ANRIL, and in some cases expression
of the adjacent CDKN2A/B tumor suppressors, but also impacts ANRIL splicing, such
that 3′-5′-linked circular noncoding ANRIL RNA species are produced. We describe how
the balance of linear and circular ANRIL RNA, determined by the Chr9p21 genotype,
regulates molecular pathways and cellular functions involved in atherogenesis. We end
with an outlook on how manipulating circular ANRIL abundance may be exploited for
therapeutic purposes.
Keywords: lncRNA (long non-coding RNA), circRNA, GWAS (genome-wide association study), eQTL analysis,
transcription, splicing, tumor suppressor proteins, cardiovascular diseases
INTRODUCTION
Since publication of the first genome-wide association studies (GWAS) of coronary artery disease
(CAD) in 2007, Chr9p21 has emerged as themost significant risk locus associated with this frequent
disease (1–4). The region contains a number of strongly interlinked SNPs within a stretch of 58
kilobases (kb) of non-protein-coding DNA. Later, the same haplotype block has been associated
with other endpoints of atherosclerosis, such as stroke (5–11), peripheral artery disease (12–14),
and also with different types of aneurysms (2, 8, 15, 16). Due to the availability of large study
cohorts and the better resolution of genetic recombination in this region, it has now become
clear that associations with other phenotypes at Chr9p21 fall in distinct haplotype blocks not
overlapping with the CAD block (Figure 1A). Closely nearby, and proximal to the CAD locus,
GWAS found associations with cancer, such as melanoma, glioma, basal cell carcinoma, and acute
lymphoblastic leukemia [see (40) for review], and also with glaucoma, and diverse proliferative or
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inflammatory diseases, such as endometriosis of the reproductive
tract (41), periodontitis (42), and platelet reactivity (43). The
region located distally to the CAD region contains a distinct
haplotype block associated with type 2 diabetes (44, 45).
In the last 10 years, GWAS have been successfully used to
increase the number of genetic loci implicated in CAD risk
inheritance. The number of CAD risk loci in the genome rose
from 56 by 2013 (24, 46–52) to 80 by 2015 (53–56), to 243 by
2017 (17). Concerning the Chr9p21 locus in these studies, the
association rose steadily from p = 5.40 × 10−23 (rs4977575)
(57), over p = 4.68−101 (rs4977574) (17) to p = 8.8 × 10−223
(rs4977574) (58). In populations of European descent, the allele
frequency is very high (0.48), leading to the situation that
approximately one-fourth of people are homozygous for the
CAD risk alleles. CAD risk SNPs on Chr9p21 have recurrently
been shown to have one of the top-ranking effect sizes [allele-
specific odds ratio (OR) for CAD> 1.3] (3, 24). Despite the extent
of effects, the Chr9p21 risk is independent of classically known
CAD risk determinants, such as dyslipidemia, diabetes mellitus,
age, and sex.
The Chr9p21 region contains at least 5 genes, which are, in
part, tightly clustered and overlapping. These include the 3.8 kb
long ANRIL non-coding RNA, and the tumor suppressors
cyclin dependent kinase inhibitor CDKN2A/p16INK4A,
CDKN2A/p14ARF , CDKN2B/p15INK4B, and methylthioadenosine
phosphorylase (MTAP). ANRIL overlaps in antisense the full
length of the p15 gene body, while sharing a bidirectional
promoter with CDKN2A. Hence, it was also termed CDKN2B
antisense RNA (CDKN2B-AS1). Only recently, the picture got
even more complex: Advances in high-throughput sequencing
and adaptions in bioinformatics mapping of RNA reads to
reference genomes have revealed that thousands of genes in
our genome produce not only mature linear RNA but also
3′-5′ covalently linked circular RNAs (circRNAs) (59). So far,
two studies have shown that a number of circular ANRIL
(circANRIL) isoforms exist, comprised of different exons,
whereby a downstream exon is fused to an upstream exon by
the enzymatic activity of the spliceosome in a reaction termed
“backsplicing” [see (60, 61) for review]. Circularizing exons
in ANRIL stemmed mostly from middle parts of the lncRNA
(Figure 1A), which are in part also shared by the linear ANRIL
isoforms. CircANRIL was found not only in many different cell
lines, but also in many primary cell types, including vascular
smooth muscle cells (VSMCs) and macrophages, as well as in
heart and vascular tissue (22, 36).
A major focus in exploring how risk is effected by Chr9p21
has been on whether genetic variation affected expression of
genes at the locus in cis (Figure 1A) or whether it elicited
gene expression changes in trans. Top CAD-associated SNPs lie
within the distal parts of long linearANRIL isoforms (Figure 1A)
and several studies have shown that they co-localize with
sequences marked by chromatin modifications, RNA polymerase
II transcription patterns and DNA motifs characteristic of bona-
fide transcriptional enhancers (19, 35, 62–65). Using expression
quantitative trait locus (eQTL) analyses in patient samples,
several groups have by now investigated if the risk alleles
at the locus were associated with the expression of specific
target genes in cis (cis-eQTLs). Whereas studies investigating
ANRIL expression have mostly used quantitative PCRs (qPCRs)
targeting different exons from the lncRNA, expression of p14,
p15, p16, or MTAP has either been investigated using genome-
wide expression arrays or isoform-specific qPCRs. Here, we focus
on studies investigating eQTLs in atherosclerosis cohorts but do
not cover studies related to other phenotypes, such as cancer,
which are reviewed elsewhere (66).
CIS-eQTLs AT Chr9p21
ANRIL expression at Chr9p21 is complex and at least 20 linear
isoforms as well as multiple circular isoforms have been reported
[www.ensembl.org, (22, 36, 39)]. In principal, linear and circular
isoforms can be distinguished by the fact that the latter derive
from a backsplice event, where splicing of a downstream exon
(e.g., exon 7) to an upstream exon (e.g., to exon 5) can be
detected. Backsplicing of ex7-5 was the most common event
observed in our own study in peripheral blood monocytes (36).
Concordantly, Burd and colleagues have reported dominant
backsplice isoforms spanning ex14-4 in peripheral blood T
lymphocytes (22). In both studies, exon 1 and exons 17-20
were not contained in circularized ANRIL (Table 1). Thus, for
classification reasons, results from studies targeting these exons
will be referred to as proximal linear isoforms (containing the
firstANRIL exons) and long linear isoforms (containing the distal
exons 17-20) (Table 1). Since both linear and circularANRILmay
contain exons from themiddle portion of the lncRNA (e.g., exons
4-16), a clear distinction as to whether linear or circular isoforms
were investigated cannot be made in cases where these exons
were targeted by qPCRs which were non-specific for backsplice
junctions (Table 1).
As one of the first studies on Chr9p21, Jarinova et al. have
shown that ANRIL expression was induced by the CAD risk
SNP rs1333049 in peripheral blood monocytes (PBMCs). No
significant effects on CDKN2A or on CDKN2B were recorded
in that study (19). Over the years, comparable quantifications
of these genes followed in whole blood, peripheral blood T
lymphocytes, lymphoblastoid cells lines, aortic smooth muscle
cells (SMCs) and in different tissue samples that are known
to have a role in atherosclerosis. For example, vascular tissues
such as carotid atherosclerotic plaque samples, samples from
aorta, mammary artery, and from the heart ventricles have been
analyzed, but also tissues like subcutaneous or omental fat have
been used (Table 1). Of the 23 cis-eQTL studies conducted in the
Chr9p21 CAD region to date, 16 investigated different isoforms
of ANRIL, out of which 10 used assays targeting proximal ANRIL
exons, 8 used assays targeting the middle region, 6 used assays
targeting downstream linear ANRIL exons, and two investigated
backsplices contained in circANRIL (Table 1). Complicating a
clear-cut interpretation, in the different studies, different risk
genotypes were used to indicate risk haplotypes. The expression
of CDKN2A and of CDKN2B was investigated in 18 studies and
MTAP in 10 studies (Table 1).
Overall, 80% of the studies investigating ANRIL expression
found an association with the Chr9p21 genotype. Here, a trend
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FIGURE 1 | ANRIL and the CAD risk locus at Chr9p21. (A) Genomic mapping of SNPs identified in a region ± 300 kb around the top-ranking sentinel SNP rs4977574
based on data of the most recent large CAD GWAS (17). Chromosome ideogram and zoom-in onto RefSeq transcripts for ANRIL, CDKN2A, CDKN2B, and MTAP
(Continued)
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FIGURE 1 | (top), regional association plot of CAD risk alleles and graph of recombination rate in the locus (middle), scaled linkage disequilibrium heatmap (D′) as
derived from the 1000Genomes Project dataset (Phase3V5, CEU) (bottom). The threshold for significance of GWAS hits is indicated as horizontal dotted line (p <
5E-8). Dots for SNPs described in Table 1 are marked in yellow. The suspected core CAD risk region, corresponding to the distal region of ANRIL, has been defined
experimentally through multiple CAD GWAS and is highlighted in red. The physical genomic map and the haplotype map are connected by oblique lines. Note that not
all RNA transcripts and isoforms are depicted, and that type 2 diabetes (T2D, highlighted blue) and cancer risk regions (highlighted gray) are shown in simplified forms.
(B) Model how the genotype at Chr9p21 controls the balance of linear and circular ANRIL RNA expression and potential molecular mechanisms of the different ANRIL
isoforms. Linear ANRIL upregulation regulates gene expression in trans and pro-adhesive, pro-proliferative, anti-apoptotic cell functions. High levels of circANRIL
inhibit over-proliferation of vascular cells by controlling rRNA maturation through impairing PES1 function in the PeBoW complex.
toward higher expression of the proximal and distal exons
contained in linear ANRIL in patients carrying the CAD-risk
allele was observed (7 of 10 and 3 of 6 studies). In contrast,
circular ANRIL was downregulated in the two published studies
in patients carrying the Chr9p21 risk haplotype. No clear
tendency was observed when assays targeting the middle region
of ANRIL were used (Table 1). This is likely explained by the
fact that these assays target both, linear and circular, ANRIL
isoforms, which seem to be inversely regulated. With respect to
the tumor suppressor genes contained at the Chr9p21 locus, 78
and 67% of the studies failed to find an association of CDKN2A
and CDKN2B with Chr9p21, respectively. When reporting an
association, specifically CDKN2B was down-regulated in the
majority of studies (94%), yet its expression was not always
anticorrelating with ANRIL expression (19, 21, 22, 29). MTAP
expression was not associated with the Chr9p21 genotype in any
of the published studies. Overall, the picture emerges that circular
ANRIL and CDKN2B tend to be down-regulated in patients
carrying the risk allele, whereas linear ANRIL isoforms tend to
be inversely regulated (Figure 1B). It is currently unclear, why
expression of p15 or of p14 and p16 were in many cases positively
correlated with ANRIL (19, 21, 22, 27, 29, 32, 34, 65). Also,
MTAP, which was not associated with Chr9p21 (Table 1), was in
some conditions anticorrelating to ANRIL, but not in all cases
or contexts (20, 34, 67). SNPs in ANRIL can hypothetically affect
enhancers in both directions, either by disrupting transcription
factor binding sites in open chromatin (68) or by increasing
enhancer activity through yet unknown primary effects (24, 65).
In summary, many studies document cis-eQTLs for ANRIL
or, separately, for CDKN2B (35). Throughout, from the existing
data, it can be concluded that these effects are cell-type specific
and combinatorial. Of note, many studies have investigated only
very small cohorts and those, simultaneously testing both ANRIL
and CDKN2B in larger cohorts (>1000 samples) identified
much stronger effects of Chr9p21 on ANRIL than on CDKN2B
(13, 33, 36). This observation might be explained by the
haplotype block structure of the region, where effects of CAD
lead SNPs are located within ANRIL but bleed through due
to linkage disequilibrium, resulting in more subtle concomitant
effects on CDKN2B expression. Another possibility is that the
Chr9p21 genotype impacts transcription enhancers at the locus
which contact and activate gene promoters affecting CAD.
The consequences of such contacts would not be expected to
be captured through traditional non-allelic RNA expression
analysis. In fact, when allelic expression control through 3D-
enhancer looping was specifically measured in a separate study
in human coronary aortic SMCs (64), physical contacts of CAD
variant-containing enhancers in the locus and the promoters of
CDKN2A, CDKN2B, and ANRIL were corroborated.
Taken together, these data suggest that genetic variationwithin
the core 9p21 CAD region relates to differential expression
not only of ANRIL, but in specific cells or conditions, also of
the CDKN2A/B tumor suppressors encoded in the locus. While
either of these factors could potentially increase cell proliferation,
or lead to unscheduled senescence, or elicit out of context
inflammatory signaling, as far as based on work with cells in vitro,
no study in humans or in mouse models has been able to
decisively implicate a downstream effector pathway in vivo.
TRANS-eQTLs AT Chr9p21 AND
MOLECULAR FUNCTIONS OF ANRIL IN
TRANSCRIPTIONAL REGULATION
As opposed to cis effects, two eQTL studies have so far detected
modest and tissue-selective differential expression of dozens
of genes associated with Chr9p21 genotype with genome-wide
significance (19, 27). Affected genes were from a broad range of
classes (AVPR2, PEAK1, FBLN1, KALRN, DAZL, STAU2, HLA-
DQA1, BTNL8, PLEKHA6, TDGF1) in whole blood (19) and
different, non-overlapping gene sets linked to tissue wounding,
cell migration and inflammatory response, when analyzing heart
tissue, plaques, aortas, and arteries (27).
Other, and in part, larger studies in vascular tissue (20),
peripheral blood mononuclear cells (PBMC, n = 2280) (33) and
in blood monocytes (n = 1490) (23) reported no significant
expression association.
Though not directly comparable, another study showed that
in macrophages cultured in vitro under stress-bearing IFNγ and
LPS stimulation, the CAD risk genotype led to differential up-
and downregulation of target genes outside the Chr9p21 locus
and yet distinct from the previously mentioned studies (IL1B,
IL12B, CASP5, CCL8, MT1A, MT1E, MUCL1, TNIP3, VCAN,
ENPP2, NDP, CD163) (30). Also ANRIL knockdown in cultured
cell lines (69–72) and overexpression of linearANRIL affected the
expression of non-overlapping gene sets in the genome in trans
(33, 36).
How ANRIL exerts trans-regulation is not known, and
despite a study that showed a physical interaction of ANRIL
with promoters of target genes (33), this role is likely not a
classical function as enhancer RNA [eRNA (73)], because it
involved both up-and down-regulated genes, and was suggested
to involve sequence homology (33). In the case of ANRIL,
trans-regulation of target genes was ascribed to an ALU motif
Frontiers in Cardiovascular Medicine | www.frontiersin.org 4 November 2018 | Volume 5 | Article 145
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in both ANRIL and the target gene promoters (33). Similarly,
an independent study found that ANRIL did not only silence
its targets, but unexpectedly also upregulated target genes: For
example, proinflammatory interleukins IL6/8 were found to be
co-stimulated by ANRIL and YY1, a transcription-regulating
factor that bound to the ANRIL RNA, especially in the context
of TNFα/NFκB signaling (70). Therefore, opposite to what
could have been expected from the reported physical interaction
of ANRIL with proteins from the repressive Polycomb group
complexes (74), ANRIL might be an activator, at least for some
trans-regulated genes (33, 70) (see chapter 4 for details). Whether
circANRIL, beyond regulating rRNA maturation, is involved
in primary transcriptional control, alone or via impacting
linear ANRIL’s function, is not known (36). Nevertheless, it is
interesting to note that circANRIL isoforms linked to CAD are
produced from exons located in the middle of the ANRIL gene
(22, 36), and as such do not include the ALU motif, which
is important for gene trans-regulation by linear ANRIL and
is located more distally in the gene (33). Thus, variation in
ANRIL RNA at the molecular level (linear vs. circular) might
impose a fundamental alteration in ANRIL effector function,
while not offering any explanation per se on how linear ANRIL
regulates genes, as scaffold for promoter-activating complexes, or
as decoy/inhibitor of repressive chromatin-modifying complexes.
Conservatively speaking, it seems possible that Chr9p21 CAD
risk genotypes affects genomic expression both in cis and in trans,
and linear ANRIL RNA may be one, but not the sole, important
effector molecule for how the Chr9p21 locus transduces such
effects (Figure 1B).
CORRELATION OF CHR9P21 GENES WITH
ATHEROSCLEROSIS SEVERITY IN
HUMANS AND MOUSE MODELS
Another piece of evidence for a functional role of ANRIL
in determining CAD risk stems from correlation analysis
with disease features in patient cohorts. Aside of the genetic
association, ANRIL levels were often increased in CAD patients,
and not only in atherosclerotic plaque tissue, but also in
circulating PBMCs or whole blood. Here, linear ANRIL levels
were positively correlated with the severity of atherosclerosis (13,
29, 75) whereas circANRIL was anticorrelated (36) (Figure 1B).
Thus, while the genotype of Chr9p21 determines the production
of atherogenic (linear) over antiatherogenic ANRIL RNA species
(circular), CAD and peripheral artery disease-dependent changes
may additionally feed into ANRIL regulation. For CDKN2B,
two studies reported a correlation of the expression with
atherosclerosis severity (34, 76), where the direction of the
correlation (downregulation in plaques) was consistent from
what could be expected from the association results. But another
study reported increased p16INK4A levels to positively correlate
with inflammation markers in plaques instead of anticorrelation
(25). Together, results from association as well as correlation
analyses have etablished ANRIL lncRNA as prime candidate at
the Chr9p21 locus.
MOLECULAR FUNCTION OF ANRIL AND
CDKN2A/B IN ATHEROGENESIS
ANRIL belongs to the group of long non-coding RNAs and
as such has been suggested to act as a molecular scaffold of
chromatin-modifying complexes that control gene expression
through modifying histone tails. Specifically, ANRIL was found
to physically interact with the CBX7 protein inside the PRC1
Polycomb complex, one of the major gene repression complexes
in cells (74). Knockdown of members of this Polycomb
group complex led to increased expression of the CDKN2A
and CDKN2B tumor suppressors in the Chr9p21 locus. Also,
ongoing RNA polymerase II transcription was important for
the association of the Polycomb proteins with the locus,
indicative of the importance of RNA for recruitment. It was
concluded that ANRIL’s function may be, at least in part, to
repress the CDKN2A and CDKN2B tumor suppressors. As a
consequence increased ANRIL levels are thought to promote
overproliferation and to be incompatible with senescence onset,
a major function of CDKN2A/B. As described in chapter 2, other
work has shown that recruitment of the Polycomb complexes
may account also for how ANRIL regulates genes in trans on
a genome-wide level: Overexpression of linear ANRIL isoforms
in cultured cells was found to promote pro-atherogenic cell
functions, such as proliferation and reduced apoptosis, and to
trigger the differential expression of hundreds of genes, in this
case without affecting CDKN2A/B suppressors. Results from
that study therefore questioned whether ANRIL regulated these
tumor suppressor genes in cis at all (36, 77).
How does circular ANRIL, whose abundances is reduced in
CAD patients, fit into this model? Both in human peripheral
blood T-lymphocytes, as well as in PBMCs, whole blood and
endatherectomy plaque tissue, circANRIL isoforms were found
to be downregulated in samples from CAD patients carrying the
Chr9p21 risk allele (22, 36). In an initial model, it was suggested
that the production of circANRIL from central ANRIL exons
would shorten the linear ANRIL lncRNA and, thereby, impaired
linear ANRIL’s function in epigenetic control of target genes (22).
In a second study, a more primary role was found for circANRIL
that was, furthermore, independent of linear ANRIL (36). Here,
circANRIL was found to be 10-fold more abundant than linear
ANRIL. Mass-spectrometric analysis of proteins interacting with
circANRIL showed that it bound to PES1 protein, a member
of the evolutionarily conserved PeBoW complex. This complex
is essential for proper rRNA-processing, that is the excision
of RNA spacer elements from pre-ribosomal rRNA precursors.
CircANRIL inhibited the activity of the PeBoW complex, as
deduced from the accumulation of unsufficiently processed (and
non-functional) 26S and 32S pre-rRNA intermediates when
circANRIL was overexpressed (36). A deficit in rRNAmaturation
caused nucleolar stress and p53 activation, culminating in
inhibition of cell proliferation and in an increase in apoptosis.
Notably, the observed functions of circANRIL were inverse to
that of linear ANRIL and, as shown by genomic knockout of
linear ANRIL exons, independent from the presence of these
lncRNA isoforms. Thus, experimental evidence from expression
analysis in vivo and from genetic experiments both indicated
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that circANRIL was anti-atherogenic. Together, linear ANRIL
confers overproliferation, and circular ANRIL protects from
overproliferation, suggesting that the genotype of Chr9p21 is
important to determine the balance of linear and circular ANRIL
levels in SMCs and macrophages, and that a dominance of linear
ANRIL in this ratio, even when small, over decades skews for
CAD (36) (Figure 1B).
Whether suppressing linearANRIL or boosting circularization
is sufficient to protect from atherosclerotic cues in vivo is
matter of ongoing research. The fact that ANRIL RNA is
not conserved beyond primates complicates the functional in
vivo analysis of the Chr9p21 locus. So far, insight on how
CAD is controlled by Chr9p21 through genetic modeling
in mouse mutants is fragmented. The genetic elements of
Chr9p21 and their relative positioning are overall syntenically
conserved in mouse chromosome 4. So far, only one study
has investigated, if deletion of a 70 kb long portion of mouse
Chr4 corresponding to the CAD haplotype block in humans
had an effect on atherosclerosis in vivo (78). This region
contains a multi-exon lncRNA, AK148321, which is, however,
likely not corresponding to human ANRIL. Mutant mice (78)
developed tumors, reminiscent of tumorigenesis associated with
mutation in the Chr9p21 region. But despite some metabolic
changes in the mutant mice and enhanced platelet activation,
no significant change in atherosclerotic fatty lesion formation
was observed (78), putting in question the validity of this mouse
model for studying ANRIL-driven atherogenesis. On the other
hand, the mutants did develop more vascular aneurysms (79),
supporting that some aspects of CAD were indeed contained in
the noncoding mouse sequence.
Overall, the picture is not yet fully clear. While the genetic
data from mice support the importance of individual noncoding
genetic elements and of some of the protein-coding tumor
suppressors for regulation of atherosclerosis and other CAD
entities, whether the lncRNA encoded in the locus regulates CAD
mechanistically via epigenetically regulating the neighboring
tumor suppressors in cis has not been determined. Nevertheless,
mouse genetics remains an interesting research avenue to explore
some aspects of Chr9p21 biology, at least relating to aneurysm,
cancer, and glaucoma formation.
SUMMARY
Starting from a GWAS signal for CAD in a “gene desert”
on Chr9p21 in 2007, research in the last decade has firmly
established this region as strongest genetic factor of human
atherosclerosis and has contributed to a better understanding of
the underlying pathophysiology. The picture has emerged that
one of the major routes how this locus controls atherosclerosis
risk is through regulating the expression of the lncRNA ANRIL
in cis, where the risk allele leads to high levels of linear ANRIL
but decreases circular ANRIL expression. Linear ANRIL has
been established as molecular scaffold guiding epigenetic protein
complexes and promoting pro-atherogentic cells functions. On
the contrary, circularization shifts ANRIL’s function toward
controlling ribosomal RNA processing and controlling protein
translation thereby promoting athero-protection (Figure 1B).
The molecular mechanisms of how the ratio of linear and
circular ANRIL is controlled by the genotype at the locus are
currently not resolved and it will be important to determine
which gene regulatory elements within the ANRIL gene are
disturbed by causal CAD risk SNPs. Experimentally exploring
details of the molecular effector mechanisms for linear ANRIL
and for circular ANRIL will be paramount, but this task will
not be trivial because linear and circular ANRIL isoforms
always co-exist and in part share the same sequence. Not last,
more nuanced relations between Chr9p21 genotype and gene
expression output can be expected to be found in the future if,
for example, analyses were to take into account cell type-specific
and context (stress, inflammation, senescence)-specific effects,
aspect that whole tissue expression profiling is currently missing.
Additionally, although it is early days, measuring the levels of
circANRIL/linear ANRIL, might offer a prognostic value and
help improve CAD risk stratification or allow to better monitor
treatment response or disease recurrence.Yet, since circANRIL
levels are reduced in plaque tissue, and since circANRIL has been
found to be anti-atherogenic with or without co-existing linear
ANRIL, increasing circANRIL abundance in patients could also
be of therapeutic relevance. Expressing circANRIL levels in the
cells of the vasculature in CAD disease models might, therefore,
be a promising next step to exploit the accumulated knowledge
on the Chr9p21 CAD risk locus.
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